Float Short %

9.73

Margin Of Safety %

Put/Call OI Ratio

0.56

EPS Next Q Diff

-0.02

EPS Last/This Y

-0.44

EPS This/Next Y

0.08

Price

20.21

Target Price

32.86

Analyst Recom

1.06

Performance Q

15.5

Upside

-287.4%

Beta

1.03

Ticker: DNLI

20 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2026-01-23	DNLI	20.33	0.15	0.00	3425
2026-01-26	DNLI	20.6	0.15	0.06	3537
2026-01-27	DNLI	21.26	0.15	0.00	3591
2026-01-28	DNLI	20.83	0.12	0.06	4150
2026-01-29	DNLI	21.61	0.12	0.01	4193
2026-01-30	DNLI	21.76	0.12	0.00	4302
2026-02-02	DNLI	22.73	0.11	0.55	4504
2026-02-03	DNLI	21.76	0.17	0.03	5230
2026-02-04	DNLI	21.28	0.17	0.00	5278
2026-02-05	DNLI	20.02	0.17	0.01	5254
2026-02-06	DNLI	21	0.17	0.02	5319
2026-02-09	DNLI	20.83	0.16	0.47	5457
2026-02-10	DNLI	19.81	0.18	0.48	5806
2026-02-11	DNLI	19.69	0.51	0.50	11793
2026-02-12	DNLI	19.26	0.51	0.17	11872
2026-02-13	DNLI	18.77	0.51	0.24	11894
2026-02-17	DNLI	19.27	0.51	3.68	11894
2026-02-18	DNLI	19.25	0.54	8.40	12129
2026-02-19	DNLI	20.23	0.55	0.10	12262
2026-02-20	DNLI	20.2	0.56	0.17	12253
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

20 items 1 of 1

20 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2026-01-23	DNLI	20.23	-13.9	229.4	-3.01
2026-01-26	DNLI	20.60	-13.4	206.5	-3.01
2026-01-27	DNLI	21.25	-13.4	200.6	-3.01
2026-01-28	DNLI	20.82	-13.4	223.2	-3.01
2026-01-29	DNLI	21.60	-13.4	198.1	-3.01
2026-01-30	DNLI	21.77	-13.4	210.8	-3.01
2026-02-02	DNLI	22.73	-13.4	195.1	-3.01
2026-02-03	DNLI	21.76	-12.9	232.2	-3.01
2026-02-04	DNLI	21.26	-12.9	224.9	-3.01
2026-02-05	DNLI	20.03	-12.9	240.1	-3.01
2026-02-06	DNLI	21.06	-12.9	191.4	-3.01
2026-02-09	DNLI	20.85	-12.9	219.2	-3.01
2026-02-10	DNLI	19.81	-12.9	236.2	-3.01
2026-02-11	DNLI	19.70	-12.9	216.9	-3.01
2026-02-12	DNLI	19.18	-12.9	226.1	-3.01
2026-02-13	DNLI	18.77	-12.9	224.3	-3.01
2026-02-17	DNLI	19.29	-12.9	201.5	-3.01
2026-02-18	DNLI	19.24	-12.9	215.3	-3.01
2026-02-19	DNLI	20.24	-12.9	-	-3.01
2026-02-20	DNLI	20.21	-12.9	-	-3.01
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

20 items 1 of 1

20 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2026-01-23	DNLI	-0.36	1.67	10.41
2026-01-26	DNLI	-0.36	2.19	10.41
2026-01-27	DNLI	-0.36	2.19	10.41
2026-01-28	DNLI	-0.36	2.19	10.62
2026-01-29	DNLI	-0.36	2.19	10.62
2026-01-30	DNLI	-0.36	2.19	10.62
2026-02-02	DNLI	-0.36	3.01	10.62
2026-02-03	DNLI	-0.36	3.01	10.62
2026-02-04	DNLI	-0.36	3.01	10.62
2026-02-05	DNLI	-0.36	3.01	10.62
2026-02-06	DNLI	-0.36	3.01	10.62
2026-02-09	DNLI	-0.36	4.01	10.62
2026-02-10	DNLI	-0.36	4.01	10.62
2026-02-11	DNLI	-0.36	4.01	9.69
2026-02-12	DNLI	-0.36	4.01	9.69
2026-02-13	DNLI	-0.36	4.01	9.69
2026-02-17	DNLI	-0.32	5.77	9.69
2026-02-18	DNLI	-0.32	5.77	9.69
2026-02-19	DNLI	-0.32	5.77	9.69
2026-02-20	DNLI	-0.32	5.77	9.73
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

20 items 1 of 1

Last Quarter Act. EPS

-0.74

Avg. EPS Est. Current Quarter

-0.76

Avg. EPS Est. Next Quarter

-0.76

Insider Transactions

-0.32

Institutional Transactions

5.77

Beta

1.03

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

74.6

Max Drawdown 5-Year %

-85.4

Target Price

32.86

P/E

Forward P/E

PEG

P/S

P/B

3.2

P/Free Cash Flow

EPS

-2.91

Average EPS Est. Cur. Y

-3.01

EPS Next Y. (Est.)

-2.94

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

1.06

Return on Equity vs Sector %

-82.9

Return on Equity vs Industry %

-65.4

EPS 1 7Days Diff

EPS 1 30Days Diff

-0.02

EBIT Estimation

Denali Therapeutics Inc.

Sector: Healthcare

Industry: Biotechnology

Employees: 517

Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases. The company develops Eclitasertib (SAR443122/DNL758) RIPK1 inhibitor program for peripheral inflammatory diseases; DNL343 eIF2B activator program for amyotrophic lateral sclerosis; BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; TAK-594/DNL593 program for frontotemporal dementia-granulin; DNL126 program for MPS IIIA (Sanfilippo Syndrome A); and DNL310 Tividenofusp alfa, an enzyme replacement therapy program for MPS II (Hunter Syndrome). Its Enzyme TransportVehicle (TV) programs include DNL952 for the treatment of Pompe disease; DNL111 for Parkinson's and Gaucher diseases; and DNL622 for Hurler syndrome (MPS I). The company's OTV programs also comprise DNL628 targeting tau for Alzheimer's disease; and DNL422 targeting alpha synuclein for Parkinson's disease, as well as antibody TV program includes DNL921 targeting Abeta for treating Alzheimer's disease. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.

stock quote shares DNLI – Denali Therapeutics Inc. Stock Price stock today

news today DNLI – Denali Therapeutics Inc. stock forecast ,stock prediction 2023 2024 2025

marketwatch DNLI – Denali Therapeutics Inc. yahoo finance google finance

stock history DNLI – Denali Therapeutics Inc. invest stock market

stock prices DNLI premarket after hours

ticker DNLI fair value insiders trading

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Upside

Beta

Ticker: DNLI

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Last Quarter Act. EPS

Average EPS Est. Cur. Y